Lyell Immunopharma, Inc.LYELNASDAQ
LOADING
|||
Debt to Equity Over Time
Trending higher, above historical average, strong compound growth.
Left:
||||
Debt-to-equity ratio
Latest
0.15
↑ 69% above average
Average (5y)
0.09
Historical baseline
Range
High:0.15
Low:0.07
CAGR
+18.0%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | 0.15 | +59.7% |
| 2023 | 0.10 | +18.7% |
| 2022 | 0.08 | +11.4% |
| 2021 | 0.07 | -4.0% |
| 2020 | 0.08 | +12.8% |
| 2019 | 0.07 | - |